Previous 10 | Next 10 |
WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to ...
EyePoint Pharmaceuticals (EYPT) announces positive safety results from Phase 1 trial of EYP-1901, an anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). The DAVIO clinical trial of EYP-1901 enrolled 17 wet AMD patients across three dose cohorts.Key safety observation...
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive safety results from its ...
WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical As...
EyePoint Pharmaceuticals (EYPT) to join the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at annual reconstitution, effective Monday, June 28, 2021.Press Release For further details see: EyePoint Pharmaceuticals to...
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company will be add...
WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Exec...
WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the completion of patient enr...
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2021 Earnings Conference Call May 05, 2021, 08:30 ET Company Participants George Elston - CFO & Head, Corporate Development Nancy Lurker - President, CEO & Director Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial O...
EyePoint Pharmaceuticals (EYPT): Q1 GAAP EPS of -$0.50 beats by $0.01.Revenue of $7.3M (-2.5% Y/Y) misses by $0.54M.Financial Outlook: Expects the cash on hand at March 31, 2021 and expected net cash inflows from the product sales to fund the current and planned operations through the en...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...